Ergomed logo

ERGO - Ergomed News Story

788p 18.0  2.3%

Last Trade - 23/09/20

Mid Cap
Market Cap £372.8m
Enterprise Value £363.9m
Revenue £68.3m
Position in Universe 591st / 1809

Ergomed plc - Change of Registered Office

Fri 15th June, 2018 3:14pm
RNS Number : 6042R
Ergomed plc
15 June 2018





Change of Registered Address


London, UK - 15 June 2018: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that it has changed its registered office address with immediate effect to:


1 Occam Court

Surrey Research Park


Surrey GU2 7HJ

United Kingdom


All other details remain the same including the Company's telephone/fax numbers and website (, which includes the information required by AIM Rule 26.








Ergomed plc

   Tel: +44 (0) 1483 503 205

Stephen Stamp (Chief Executive Officer)

Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black (Joint Broker)

N+1 Singer

Tel: +44 (0) 20 7496 3000

Aubrey Powel (Joint Broker)

Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

Ivar Milligan / Philippa Gardner

MC Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke



About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit:



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.